VACOP-B vs VACOP-B+ABMT for aggressive non-Hodgkin's lymphoma. Results of a prospective randomised trial.

被引：0
|
作者：
Santini, G [1 ]
Salvagno, L [1 ]
Leoni, P [1 ]
Chisesi, T [1 ]
Rizzoli, V [1 ]
机构：
[1] S Martino Hosp, Dept Haematol, Genova, Italy
来源：
EXPERIMENTAL HEMATOLOGY | 1998年 / 26卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
234
引用
收藏
页码：746 / 746
页数：1
相关论文
共 50 条
  • [31] Venous thromboembolic events in patients with diffuse large B cell non-Hodgkin's lymphoma.
    Komrokji, RS
    Uppal, NP
    Khorana, AA
    Lyman, GH
    Kaplan, KL
    Fisher, RI
    Francis, CW
    BLOOD, 2004, 104 (11) : 219B - 219B
  • [32] Novel aurora plus Bruton's tyrosine kinase-targeted therapies for aggressive B-cell non-Hodgkin's lymphoma.
    Mahadevan, Daruka
    Morales, Carla
    Karp, Russell
    Cooke, Laurence
    Lyons, John
    Singh, Juswinder
    Di, Wenqing
    CANCER RESEARCH, 2013, 73 (08)
  • [33] CONSTITUTIVE ACTIVATION OF THE CANONICAL WNT PATHWAY IN AGGRESSIVE B CELL NON-HODGKIN'S LYMPHOMA
    Huang, H.
    Qu, Q.
    Chen, F.
    Zhong, J.
    HAEMATOLOGICA, 2014, 99 : 689 - 689
  • [34] Aggressive non-Hodgkin's lymphoma: T-cell versus B-cell
    Liang, R
    Todd, D
    Ho, FCS
    HEMATOLOGICAL ONCOLOGY, 1996, 14 (01) : 1 - 6
  • [35] Durability of complete response after blinatumomab therapy for refractory/relapsed aggressive B-cell non-Hodgkin lymphoma.
    Viardot, Andreas
    Hess, Georg
    Bargou, Ralf C.
    Morley, Nicholas
    Gritti, Giuseppe
    Iskander, Karim
    Cohan, David
    Zhang, Alicia
    Franklin, Janet
    Coyle, Luke
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [36] Preliminary results from a phase II study of lenalidomide monotherapy in Relapsed/Refractory aggressive non-Hodgkin's lymphoma.
    Wiemik, Peter H.
    Lossos, Izidore
    Tuscano, Joseph
    Justice, Glen
    Vose, Julie M.
    Pietronigro, Dennis
    Takeshita, Kenichi
    Ervin-Haynes, Annette
    Zeldis, Jerome B.
    Habermann, Thomas M.
    BLOOD, 2006, 108 (11) : 160A - 161A
  • [37] Long term results with a dose density therapy for aggressive non-Hodgkin's lymphoma. A study of the "ARGE medikamentoese tumortherapie".
    Fridrik, MA
    Hausmaninger, H
    Linkesch, W
    Greil, R
    Michlmayr, G
    Krieger, O
    Baldinger, C
    Klocker, J
    Pont, J
    Radaszkiewicz, T
    BLOOD, 2001, 98 (11) : 135A - 135A
  • [38] Preliminary results of a phase II trial of pegylated liposomal doxorubicin (Doxil), rituxan, cyclophosphamide, vincristine, and prednisone (DR-COP) in aggressive B-cell non-Hodgkin's lymphoma.
    Tulpule, A
    Khan, AU
    Mohrbacher, A
    Weitz, IC
    Espina, BM
    Boswell, WD
    Nathwani, BN
    Levine, AM
    BLOOD, 2003, 102 (11) : 286B - 286B
  • [39] High prevalence of hepatitis B virus infection in patients with aggressive B cell non-Hodgkin’s lymphoma in China
    Chaoyu Wang
    Bing Xia
    Qiaoyang Ning
    Haifeng Zhao
    Hongliang Yang
    Zhigang Zhao
    Xiaofang Wang
    Yafei Wang
    Yong Yu
    Yizhuo Zhang
    Annals of Hematology, 2018, 97 : 453 - 457
  • [40] Intensive sequential chemotherapy followed by rituximab in poor-risk aggressive non-Hodgkin's lymphoma: Preliminary results of the ISC 98 trial.
    Bouabdallah, R
    Sebban, C
    Coso, D
    Vey, N
    Biron, P
    Lepeu, G
    Chabannon, C
    Xerri, L
    Faucher, C
    Stoppa, AM
    Gastaut, A
    Maraninchi, D
    BLOOD, 2002, 100 (11) : 296B - 296B
12345